Shares of Elanco Animal Health Inc (ELAN) are soaring 17.67% in Wednesday's trading session following the company's impressive first-quarter 2025 results and an upward revision of its full-year revenue guidance. The animal health company demonstrated robust performance across key financial metrics, significantly surpassing analyst expectations.

Elanco reported adjusted earnings per share of $0.37 for Q1, beating the analyst consensus estimate of $0.31 by 19.35% and marking an 8.82% increase from the same period last year. The company's quarterly revenue of $1.19 billion also exceeded expectations, coming in above the projected $1.17 billion. Notably, Elanco's adjusted EBITDA reached $276 million, well above the estimated $249.2 million, while adjusted net income stood at $184 million, surpassing the expected $153.7 million.

In light of its strong performance, Elanco raised its 2025 revenue guidance to a range of $4.51 billion to $4.58 billion, up from the previous forecast of $4.45 billion to $4.51 billion. The company also increased its 2025 innovation revenue target to between $660 million and $740 million, further boosting investor confidence in the company's growth prospects. Despite headwinds from tariffs and foreign exchange rates, Elanco maintained its full-year adjusted earnings guidance of $0.80 to $0.86 per share, demonstrating the company's ability to navigate challenges while delivering growth.